This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Juno Therapeutics Inc.

Drug Names(s): JCAR-017

Description: JCAR017 is a product comprised of autologous chimeric antigen receptor (CAR) modified T cells. CD4 and CD8 T cells are collected from the patient through aphresis, transduced with a lentivirus to express a CD19 CAR and a truncated EGFR (EGFRt) that has no signaling capacity, and expanded in culture. The expression of EGFRt allows for cetuximab depletion of the CAR T cells in the case of acute patient toxicity or ongoing remission.

Like JCAR014, JACR017 utilizes a 1:1 ratio of CD4+ and CD8+ T cells, which may improve efficacy while allowing for lower cell doses. The chimeric receptor utilizes a 4-1BB costimulatory domain.

Deal Structure: Juno and Celgene
In June 2015, Celgene and Juno Therapeutics announced a global collaboration for the development and commercialization of immunotherapies. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno's oncology and cell therapy auto-immune product candidates, including Juno's CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen (BCMA) is excluded as a target in this collaboration.

For Juno-originated programs co-developed under the collaboration: